Context Therapeutics
NASDAQ: CNTXPhiladelphia, US · Founded 2021 · Delaware corporation · 2 known investors
Find your way into Context Therapeutics
192 people in our graph share verified history with the Context Therapeutics team — schools, employers, funds. One of them is your warm intro.
Tige Savageunlockedknows Jennifer Minai-Azary · together at University of Michigan - Stephen M. Ross School of Business (overlapped)
×4knows the team · via University of Michigan - Stephen M. Ross School of Business
×3knows the team · via Memorial Sloan-Kettering Cancer Center
×3knows the team · via The Childrens Hospital of Philadelphia
knows the team · via William Penn Charter School
Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.
Founders & leadership
Context Therapeutics was founded in 2021 by Martin Lehr.
ML
Martin LehrinFounder · CEO and DirectorMartin Lehr is the founder of Context Therapeutics, a clinical-stage company developing T cell engaging bispecific antibody therapies for solid tumors, with a pipeline targeting antigens including Claudin 6, mesothelin, and Nectin-4.
JM
Jennifer Minai-AzaryinChief Financial OfficerJennifer Minai-Azary is an executive officer at Context Therapeutics, a clinical-stage company developing T cell engaging bispecific antibody therapies for solid tumors. She has held finance leadership roles focused on financial reporting, corporate transactions, governance, and internal controls.
AL
Alex LevitNamed on SEC filing
LB
Linda Beth WestNamed on SEC filing
RJ
Richard Jay BermanNamed on SEC filing
PK
JE
Jennifer Evans StaceyNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$111.7M disclosed across 2 of 3 rounds · 2020–2024
▶$100MraisedMay 2024 · 26 investors · PharmaceuticalsRule 506(b)
▶$100MraisedMay 2024 · 26 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Alex LevitExecutive Officer
- Linda Beth WestDirector
- Martin Albert LehrExecutive Officer, Director
- Richard Jay BermanDirector
- Philip KantoffDirector
- Jennifer Minai-AzaryExecutive Officer
- Jennifer Evans StaceyDirector
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $5M
- Placement agents
- Piper Sandler & Co.
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapKite Pharma37 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Power35 shared keywordsPower builds a patient-friendly platform to discover and enroll in clinical trials, serving patients seeking access to research studies and researchers seeking to improve patient recruitment. The company operates in the healthcare technology and clinical research industry.
Click Therapeutics34 shared keywordsClick Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.
Solu34 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Century Therapeutics, Inc.34 shared keywordsCentury Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer. The company aims to make cell therapies more effective, tolerable, accessible and affordable than existing treatments.
Companies competing with Context Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Context Therapeutics do?
- Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.
- Who founded Context Therapeutics?
- Context Therapeutics was founded by Martin Lehr in 2021.
- Who are Context Therapeutics's investors?
- Context Therapeutics's investors include Nextech Invest, Torrey Pines Investment.
- How much funding has Context Therapeutics raised?
- Context Therapeutics has disclosed $111.7M raised across 2 of its 3 known rounds.
- Where is Context Therapeutics headquartered?
- Context Therapeutics is headquartered in Philadelphia, US.